CN111788221B - 具有与FcRn增强的结合及延长的半衰期的Fc变体 - Google Patents

具有与FcRn增强的结合及延长的半衰期的Fc变体

Info

Publication number
CN111788221B
CN111788221B CN201980015900.4A CN201980015900A CN111788221B CN 111788221 B CN111788221 B CN 111788221B CN 201980015900 A CN201980015900 A CN 201980015900A CN 111788221 B CN111788221 B CN 111788221B
Authority
CN
China
Prior art keywords
amino acid
domain
acid position
binding polypeptide
human igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980015900.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN111788221A (zh
Inventor
邱华伟
B·麦肯斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65520379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111788221(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CN202411307275.XA priority Critical patent/CN119350481A/zh
Publication of CN111788221A publication Critical patent/CN111788221A/zh
Application granted granted Critical
Publication of CN111788221B publication Critical patent/CN111788221B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980015900.4A 2018-01-26 2019-01-25 具有与FcRn增强的结合及延长的半衰期的Fc变体 Active CN111788221B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411307275.XA CN119350481A (zh) 2018-01-26 2019-01-25 具有与FcRn增强的结合及延长的半衰期的Fc变体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862622468P 2018-01-26 2018-01-26
US62/622,468 2018-01-26
PCT/US2019/015204 WO2019147973A1 (en) 2018-01-26 2019-01-25 Fc variants with enhanced binding to fcrn and prolonged half-life

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411307275.XA Division CN119350481A (zh) 2018-01-26 2019-01-25 具有与FcRn增强的结合及延长的半衰期的Fc变体

Publications (2)

Publication Number Publication Date
CN111788221A CN111788221A (zh) 2020-10-16
CN111788221B true CN111788221B (zh) 2026-02-13

Family

ID=65520379

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980015900.4A Active CN111788221B (zh) 2018-01-26 2019-01-25 具有与FcRn增强的结合及延长的半衰期的Fc变体
CN202411307275.XA Pending CN119350481A (zh) 2018-01-26 2019-01-25 具有与FcRn增强的结合及延长的半衰期的Fc变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411307275.XA Pending CN119350481A (zh) 2018-01-26 2019-01-25 具有与FcRn增强的结合及延长的半衰期的Fc变体

Country Status (16)

Country Link
US (1) US20190263934A1 (https=)
EP (1) EP3743441A1 (https=)
JP (3) JP7399880B2 (https=)
KR (2) KR102748986B1 (https=)
CN (2) CN111788221B (https=)
AU (2) AU2019212638B2 (https=)
BR (1) BR112020015006A2 (https=)
CA (1) CA3089602A1 (https=)
CO (1) CO2020010269A2 (https=)
IL (2) IL318916A (https=)
MX (2) MX2020007882A (https=)
MY (1) MY203898A (https=)
PH (1) PH12020551134A1 (https=)
SG (1) SG11202006905YA (https=)
TW (1) TW201940512A (https=)
WO (1) WO2019147973A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7399880B2 (ja) * 2018-01-26 2023-12-18 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
EP4004039A2 (en) * 2019-07-25 2022-06-01 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
CN114746120B (zh) 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
US11434276B2 (en) * 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
MX2023004933A (es) * 2020-10-29 2023-06-06 Formycon Ag Proteinas de fusion de ace2 y usos de las mismas.
US12297273B2 (en) 2021-05-27 2025-05-13 Sanofi Fc variant with enhanced affinity to Fc receptors and improved thermal stability
MX2024002150A (es) 2021-08-20 2024-03-08 Intervet Int Bv Anticuerpos y proteinas de fusion de igg con una semivida prolongada.
WO2023244276A2 (en) * 2021-10-13 2023-12-21 The Wistar Institute Of Anatomy And Biology DNA ENCODED ANTIBODIES WITH Fc MODIFICATIONS
IL317227A (en) 2022-05-27 2025-01-01 Sanofi Sa Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering
CN116162171B (zh) * 2022-10-13 2025-06-03 深圳市百士通科技开发有限公司 抗体突变方法在治疗性抗体药物中的应用
KR20250094703A (ko) 2022-10-25 2025-06-25 아블린쓰 엔.브이. 향상된 효과기 기능을 갖는 당조작된 Fc 변이체 폴리펩타이드
AR131281A1 (es) 2022-12-05 2025-03-05 Sanofi Sa Proteínas de unión al receptor de transferrina
US20250154262A1 (en) 2023-10-25 2025-05-15 Ablynx N.V. Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
WO2025101094A1 (en) * 2023-11-08 2025-05-15 Ооо «Geropharm» Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2026022712A1 (en) 2024-07-23 2026-01-29 Sanofi Cereblon ligase modulator and bcma nk cell engager combination therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
HU230769B1 (hu) * 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
KR20070057839A (ko) * 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2373689A1 (en) * 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
HRP20160422T1 (hr) * 2009-12-23 2016-05-20 Synimmune Gmbh Protutijela protiv flt3 postupci njihove upotrebe
WO2011089211A1 (en) * 2010-01-22 2011-07-28 Synimmune Gmbh Anti-cd133 antibodies and methods of using the same
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
JP6322411B2 (ja) * 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
RU2687043C2 (ru) * 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
RS59340B1 (sr) * 2014-11-06 2019-10-31 Hoffmann La Roche Varijante fc regiona sa modifikovanim vezivanjem za fcrn i metode upotrebe
EP3218402A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-il-1beta antibodies and methods of use
SG11201900616UA (en) * 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
JP7399880B2 (ja) * 2018-01-26 2023-12-18 ジェンザイム・コーポレーション ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体

Also Published As

Publication number Publication date
MY203898A (en) 2024-07-23
KR20250008975A (ko) 2025-01-16
EP3743441A1 (en) 2020-12-02
BR112020015006A2 (pt) 2020-12-29
KR102748986B1 (ko) 2025-01-02
AU2019212638A1 (en) 2020-09-17
CN111788221A (zh) 2020-10-16
MX2020007882A (es) 2020-12-03
IL276286A (en) 2020-09-30
US20190263934A1 (en) 2019-08-29
NZ767453A (en) 2025-03-28
CO2020010269A2 (es) 2020-12-10
JP2026021377A (ja) 2026-02-10
IL276286B1 (en) 2025-03-01
RU2020128177A (ru) 2022-02-28
SG11202006905YA (en) 2020-08-28
CN119350481A (zh) 2025-01-24
TW201940512A (zh) 2019-10-16
MX2025009543A (es) 2025-09-02
KR20200115568A (ko) 2020-10-07
IL318916A (en) 2025-04-01
JP7399880B2 (ja) 2023-12-18
JP2021511830A (ja) 2021-05-13
AU2019212638B2 (en) 2025-04-03
CA3089602A1 (en) 2019-08-01
PH12020551134A1 (en) 2021-05-31
IL276286B2 (en) 2025-07-01
AU2025204826A1 (en) 2025-07-17
JP2024026255A (ja) 2024-02-28
WO2019147973A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CN111788221B (zh) 具有与FcRn增强的结合及延长的半衰期的Fc变体
CN114466663B (zh) 以FcRn拮抗剂治疗抗体介导的障碍的方法
JP7165996B2 (ja) 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤
US20250376526A1 (en) Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
WO2021064153A1 (en) Hybrid antibody
KR20260047593A (ko) 최적화된 Fc 분자
RU2795592C2 (ru) Варианты fc с повышенным связыванием с fcrn и пролонгированным периодом полувыведения
BR122024014725A2 (pt) Usos de um antagonista de fcrn no tratamento de distúrbios mediados por anticorpos com antagonistas de fcrn, polipeptídeos isolados, e composições farmacêuticas compreendendo os mesmos
EA040482B1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant